What We're Reading: Page 147
Industry reads hand-picked by our editors
Jun 30, 2021
-
The New York Times
Mixing Pfizer, AstraZeneca Vaccines Gives Strong Covid Protection, Study Finds
-
Kaiser Health News
States Step Up Push to Regulate Pharmacy Drug Brokers
-
The Wall Street Journal
Why Vaccinated Athletes Are Testing Positive for Coronavirus
Jun 29, 2021
Jun 28, 2021
-
The Wall Street Journal
Johnson & Johnson Settles New York Opioid Case for $230 Million
-
The Atlantic
The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better
-
FierceBiotech
AstraZeneca names Galbraith as Baselga successor in cancer R&D
-
Reuters
Idorsia to trial self-injection drug for heart attack victims
Jun 25, 2021
Jun 24, 2021
Jun 23, 2021
-
HuffPost
Can America Finally Do Something On Drug Prices? This Democratic Senator Thinks So.
-
Caixin Global
China Approves Its First CAR-T Cell Therapy
-
Evaluate Vantage
EQRX vows to slash drug prices where others have failed
-
STAT
Peter Bach, industry critic, joins company aiming to make liquid biopsies
Jun 22, 2021
-
The New York Times
New Alzheimer’s Drug Could Cost the Government as Much as It Spends on NASA
-
STAT
BIO's chief on the FDA commissioner rumors, drug pricing, and IP rights
-
Bloomberg
Amarin Rebuffed in High Court Bid to Revive Vascepa Patents
-
The Boston Globe
Pear Therapeutics to go public in $1.6 billion SPAC deal to treat diseases with software
Previous
